Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Hepatocellular Carcinoma

New Protocol: Tremelimumab and Durvalumab for HCC

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Pembrolizumab for Early-Stage NSCLC

Ulas D. Bayraktar, MD

GastroEsophageal Cancer

New Reference: Trastuzumab Deruxtecan in her2-Positive Advanced Gastroesophageal Cancer

Ulas D. Bayraktar, MD

Breast Cancer

New Indication: Adjuvant Ribociclib and Endocrine Therapy in Breast Cancer

Ulas D. Bayraktar, MD

Prostate Cancer

New Indication: Talazoparib and Enzalutamide in Metastatic CRPC

Ulas D. Bayraktar, MD

Renal Cell Carcinoma

New Protocol: Belzutifan and Cabozantinib for Advanced RCC

Ulas D. Bayraktar, MD

Biliary Tract Cancer

New Protocol: Tucatinib and Trastuzumab in her2-Positive Biliary Tract Cancer

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Reference: Encorafenib and Binimetinib in bRAF V600E Mutated NSCLC

Ulas D. Bayraktar, MD

GastroEsophageal Cancer

New Protocol: Trastuzumab, Ramucirumab, and PACLitaxel for her2-Positive Advanced Gastroesophageal Cancer

Ulas D. Bayraktar, MD

Hepatocellular Carcinoma

New Protocol: Tremelimumab and Durvalumab for HCC

Open-label, phase 3 trial Unresectable hepatocellular carcinoma and no previous systemic treatment Tremelimumab (300 mg, one dose) plus durvalumab (1500 mg every 4 weeks; STRIDE,

Non-Small Cell Lung Cancer

New Indication: Pembrolizumab for Early-Stage NSCLC

A Phase III placebo-controlled, Randomized, Open-label trial (KEYNOTE-671) Resectable, early stage (stage II and III) NSCLC Arm A: Pembrolizumab + chemotherapyS->Pembrolizumab (

GastroEsophageal Cancer

New Reference: Trastuzumab Deruxtecan in her2-Positive Advanced Gastroesophageal Cancer

Single-arm, multicenter, phase II trial HER2 positive, unresectable or metastatic gastric or gastro-oesophageal junction cancer, progressive disease on or after first-line therapy

New Indication: Adjuvant Ribociclib and Endocrine Therapy in Breast Cancer

A Phase III Multi-center, Randomized, Open-label trial (NATALEE) Hormone Receptor-positive, HER2-negative Early Breast Cancer (Stage IIa-III) Ribociclib (400 mg/day) + ET (n=2549)

Prostate Cancer

New Indication: Talazoparib and Enzalutamide in Metastatic CRPC

Double-blind, placebo-controlled phase 3 trial (TALAPRO-2) Previously untreated, CRPC Enzalutamide + talazoparib (n=402) vs. Enzalutamide+ PBO (n=403

Renal Cell Carcinoma

New Protocol: Belzutifan and Cabozantinib for Advanced RCC

Phase II, single-arm, open-label, multicenter study Locally advanced or metastatic clear cell renal cell carcinoma had previously received immunotherapy and up to two systemic tre

Biliary Tract Cancer

New Protocol: Tucatinib and Trastuzumab in her2-Positive Biliary Tract Cancer

Phase II, basket study (SGNTUC-019) Previously treated with and progressed after ≥1 line of systemic therapy for HER2-positive metastatic disease. Tucatinib (TUC) + Trastuzumab

Non-Small Cell Lung Cancer

New Reference: Encorafenib and Binimetinib in bRAF V600E Mutated NSCLC

Phase II, single-arm study (PHAROS) Treatment-naïve and previously treated with BRAFV600E-mutant metastatic NSCLC Encorafenib +Bininmetinib q28 (n=98)

GastroEsophageal Cancer

New Protocol: Trastuzumab, Ramucirumab, and PACLitaxel for her2-Positive Advanced Gastroesophageal Cancer

Open-label, multicenter, phase Ib/II trial HER2-positive advanced G/GEJ cancer that progressed from trastuzumab-containing first-line chemotherapy with fluoropyrimidine and platin

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag